


ADVANCES IN

*Metabolic Disorders*



Volume 7

1977年 3月 1日

ADVANCES IN

# *Metabolic Disorders*

Edited by

**Rachmiel Levine**

*City of Hope Medical Center  
Duarte, California*

**Rolf Luft**

*Department of Endocrinology  
and Metabolism  
Karolinska sjukhuset  
Stockholm, Sweden*

VOLUME 7

*Including the Proceedings of a Symposium on Insulin,  
held at the City of Hope Medical Center,  
Duarte, California, 1972*



1974



ACADEMIC PRESS NEW YORK • SAN FRANCISCO • LONDON

A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1974, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

*United Kingdom Edition published by*

ACADEMIC PRESS, INC. (LONDON) LTD.

24/28 Oval Road, London NW1

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 64-14568

ISBN 0-12-027307-1

PRINTED IN THE UNITED STATES OF AMERICA

## Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

### CHARLES H. BEST

*Department of Physiology, and Banting and Best Department of Medical Research, Charles H. Best Institute, University of Toronto, Toronto, Ontario, Canada (141)*

### E. CERASI

*Department of Endocrinology and Metabolism, Karolinska Hospital, Stockholm, Sweden (193)*

### J. GERICH

*Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California (155)*

### G. M. GRODSKY

*Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California (155)*

### KERSTIN HALL

*Department of Endocrinology and Metabolism, Karolinska Hospital, Stockholm, Sweden (1)*

### J. KARAM

*Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California (155)*

### PAUL E. LACY

*Department of Pathology, Washington University School of Medicine, St. Louis, Missouri (171)*

**H. LAUBE**

*Division of Endocrinology and Metabolism, Center for Internal Medicine and Pediatrics, Ulm University, Ulm, Germany (243)*

**S. LEVIN**

*Metabolic Research Unit and Department of Biochemistry and Biophysics, University of California, San Francisco, California (155)*

**RACHMIEL LEVINE**

*City of Hope Medical Center, Duarte, California (183)*

**NORMAN G. LEVINSKY**

*Department of Medicine, Boston University School of Medicine, and Evans Memorial Department of Clinical Research, University Hospital, Boston, Massachusetts (37)*

**J. LINDSTEN**

*Department of Clinical Genetics, Karolinska Hospital, Stockholm, Sweden (73)*

**ROLF LUFT**

*Department of Endocrinology and Metabolism, Karolinska Hospital, Stockholm, Sweden (1, 193)*

**RICHARD J. MAHLER**

*Department of Metabolism and Endocrinology, City of Hope Medical Center, Duarte, California (213)*

**E. F. PFEIFFER**

*Department of Endocrinology and Metabolism, Center for Internal Medicine and Pediatrics, University of Ulm, Ulm, Germany (243)*

**N. RYMAN**

*Department of Genetics, University of Stockholm, Stockholm, Sweden (73)*



**SHLOMO SAMUELOFF**

*Department of Physiology, Hebrew University-Hadassah Medical School, Jerusalem, Israel (95)*

**H. SANDO**

*The Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Hongo, Tokyo, Japan (155)*

## *Contents of Previous Volumes*

### **Volume 1**

GLYCOGEN STORAGE DISEASE

*H. G. Hers*

THE PARATHYROIDS

*G. D. Aurbach and John T. Potts, Jr.*

MITOCHONDRIAL RESPIRATORY CONTROLS: BIOCHEMICAL, PHYSIOLOGICAL,  
AND PATHOLOGICAL ASPECTS

*Lars Ernster and Rolf Luft*

OSTEOPOROSIS

*B. E. C. Nordin*

BASAL METABOLIC RATE AND THYROID HORMONES

*J. R. Tata*

INSULIN ANTAGONISTS AND INHIBITORS

*J. Vallance-Owen*

ALDOSTERONE: ITS BIOCHEMISTRY AND PHYSIOLOGY

*John H. Laragh and William G. Kelley*

FOLIC ACID DEFICIENCY IN MAN AND ITS INTERRELATIONSHIP WITH  
VITAMIN B<sub>12</sub> METABOLISM

*A. Leonard Lohby and Jack M. Cooperman*

AUTHOR INDEX—SUBJECT INDEX

### **Volume 2**

GOUT

*James B. Wyngaarden*

NITROGEN-RETAINING STEROIDS AND THEIR APPLICATION IN DISEASE

*A. Querido and A. A. H. Kassenaar*

MACROGLOBULINEMIA

*Jan Waldenström*

TESTING THE FUNCTIONAL CAPACITY OF THE TRYPTOPHAN-NIACIN PATH-  
WAY IN MAN BY ANALYSIS OF URINARY METABOLITES

*J. M. Price, R. R. Brown, and Norma Yess*

THE SYNDROME OF TESTICULAR FEMINIZATION

*A. Louis Southren*

AUTHOR INDEX—SUBJECT INDEX

**Volume 3**

KETOGENESIS AND ITS REGULATION

*O. Wieland*

SPONTANEOUS DIABETES AND/OR OBESITY IN LABORATORY RODENTS

*Albert E. Renold*

ETHANOL-INDUCED HYPOGLYCEMIA

*Leonard L. Madison*

HORMONAL SYNDROMES ASSOCIATED WITH NEOPLASIA

*Mortimer B. Lipsett*

METABOLIC DISORDERS OF THE OVARY

*Bruno Lunenfeld, Aliza Eshkol, Vaclav Insler, and Zaki Kraiem*

THE NATURE AND SIGNIFICANCE OF THE LONG-ACTING THYROID  
STIMULATOR

*Joseph P. Kriss*

THYROID AUTOANTIBODIES IN THYROID DISEASES

*Noel R. Rose and Ernest Witebsky*

ERYTHROPOIETIN

*Clifford W. Gurney*

AUTHOR INDEX—SUBJECT INDEX

**Volume 4**

INTESTINAL FACTORS IN THE REGULATION OF INSULIN SECRETION

*Vincent Marks and Ellis Samols*

ANTIDIURETIC HORMONE SYNTHESIS, RELEASE, AND ACTION UNDER NORMAL  
AND PATHOLOGICAL CIRCUMSTANCES

*Niels A. Thorn*



## Contents of Previous Volumes

xv

### DISACCHARIDASE DEFICIENCY

*David H. Alpers and Kurt J. Isselbacher*

### HORMONAL CONTROL OF FETAL DEVELOPMENT AND METABOLISM

*Alfred Jost and Luc Picon*

### THE METABOLISM OF THE PLACENTA

*Andrew J. Szabo and Richard D. Grimaldi*

### METABOLIC ASPECTS OF OBESITY

*E. S. Gordon*

### THE USE OF LIQUID FORMULA DIETS IN METABOLIC STUDIES:

#### 15 YEARS' EXPERIENCE

*E. H. Ahrens, Jr.*

### AUTHOR INDEX—SUBJECT INDEX

## Volume 5

### HYPOTHALAMIC CONTROL OF THE SECRETION OF

#### ADENOHYPHYSIAL HORMONES

*Roger Guillemin*

### ADRENOCORTICAL CONTROL OF EPINEPHRINE SYNTHESIS IN HEALTH AND DISEASE

*B. J. Wurtman and L. A. Pohorecky*

### THE RELATIONSHIP BETWEEN ANGIOTENSIN AND ALDOSTERONE

*G. W. Boyd and W. S. Petri*

### THE METABOLIC INFLUENCE OF PROGESTINS

*Richard L. Landau and James T. Poulos*

### THE THYMUS GLAND: EXPERIMENTAL AND CLINICAL STUDIES OF ITS ROLE IN THE DEVELOPMENT AND EXPRESSION OF IMMUNE FUNCTION

*Allan L. Goldstein and Abraham White*

### CONTROL OF GLUCOSE METABOLISM IN THE HUMAN FETUS AND NEWBORN INFANT

*Peter A. J. Adam*

### HUMAN ADIPOSE TISSUE DYNAMICS AND REGULATION

*Per Björntorp and Jan Östman*

### CORONARY DISEASE AND CARBOHYDRATE AND FAT ABNORMALITIES

*Michael V. Herman and Richard Gorlin*

### AUTHOR INDEX—SUBJECT INDEX

## Volume 6

## THE ROLE OF THE SKIN IN CARBOHYDRATE METABOLISM

*John A. Johnson and Ramon M. Fusaro*

ON THE TRANSMISSION OF ALLOXAN DIABETES AND  
OTHER DIABETOGENIC INFLUENCES

*Martin G. Goldner and Gabriel Spergel*

## GLUCAGON AND DIABETES MELLITUS

*Roger H. Unger*

RECENT CONTRIBUTIONS TO THE STUDY OF DIABETIC  
ANGIOPATHY AND NEUROPATHY

*Knud Lundbaek*

## DISORDERS DUE TO ENZYME DEFECTS IN THE RED BLOOD CELL

*Ernest Beutler*

## THE PINEAL GLAND—A NEUROENDOCRINE TRANSDUCER

*R. Collu and F. Fraschini*

## CALCITONIN IN METABOLIC DISORDERS

*Asher Haymovits and John F. Rosen*

## AUTHOR INDEX—SUBJECT INDEX

# Contents

|  |      |
|--|------|
| Contributors . . . . .                 | ix   |
| Contents of Previous Volumes . . . . . | xiii |

## GROWTH HORMONE AND SOMATOMEDIN

KERSTIN HALL AND ROLF LUFT

|  |    |
|--|----|
| I. Introduction . . . . .  | 1  |
| II. Sulfation Factor—Somatomedin . . . . .                               | 3  |
| III. Bioassay of Somatomedin . . . . .                                   | 4  |
| IV. Occurrence of Somatomedin in Serum . . . . .                         | 9  |
| V. Purification of Somatomedin . . . . .                                 | 13 |
| VI. Mechanism of Production of Somatomedin . . . . .                     | 17 |
| VII. Biological Action of Purified Somatomedin <i>in Vitro</i> . . . . . | 20 |
| VIII. Relations between Somatomedins and Other Growth Factors . . . . .  | 25 |
| IX. Conclusions . . . . .  | 29 |
| References . . . . .   | 31 |

## NATRIURETIC HORMONES

NORMAN G. LEVINSKY

|   |    |
|---|----|
| I. Introduction . . . . .   | 38 |
| II. An Outline of Current Concepts of the Regulation<br>of Renal Sodium Excretion . . . . . | 39 |
| III. Cross-Circulation and Related Studies . . . . .  | 46 |
| IV. <i>In Vitro</i> Assays . . . . .  | 51 |
| V. "Natriuretic" Assays . . . . .   | 56 |
| VI. Other Natriuretic Agents . . . . .  | 59 |
| VII. Site of Secretion and Chemical Nature . . . . .  | 63 |
| VIII. Speculations . . . . .  | 65 |
| References . . . . .  | 67 |

## METHODOLOGICAL ASPECTS ON THE ESTIMATION OF GENETIC EFFECTS OF ENVIRONMENTAL AGENTS IN MAN

N. RYMAN AND J. LINDSTEN

|  |    |
|--|----|
| I. Introduction . . . . .  | 73 |
| II. Changes in Selection . . . . .   | 74 |
| III. Changes in Mutation Frequency . . . . .   | 78 |
| IV. Parameters That Possibly Might Reflect Changes in the Genetic Material . . . . . | 91 |
| V. Summary . . . . .   | 92 |
| References . . . . .   | 93 |

## METABOLIC ASPECTS OF DESERT ADAPTATION (MAN)

SHLOMO SAMUELOFF

|   |     |
|---|-----|
| I. Introduction . . . . .   | 95  |
| II. Methodology of Energy Metabolism Studies . . . . .  | 96  |
| III. Adaptive Changes in Man's Basal Metabolism in Hot Environment . . . . .                                | 100 |
| IV. Man's Body Temperature, Energy Expenditure, and Work Capacity in Desert Climate . . . . .               | 105 |
| V. Food Intake, Nutrients, and Water Metabolism in Desert Conditions . . . . .                              | 113 |
| VI. Acid-Base Balance in Blood of Man in the Desert . . . . .   | 120 |
| VII. The Endocrine Background for Metabolic Changes under Desert Conditions . . . . .                       | 123 |
| VIII. Some Insights into the Cellular Mechanisms of the Metabolic Changes during Exposure to Heat . . . . . | 128 |
| References . . . . .  | 131 |

## Proceedings of a Symposium on Insulin City of Hope Medical Center Duarte, California, February 13, 1972

### PHILOSOPHY AND OUTLOOK

CHARLES H. BEST

|                |     |
|----------------|-----|
| Text . . . . . | 141 |
|----------------|-----|

## SYNTHESIS AND SECRETION OF INSULIN IN DYNAMIC PERFUSION SYSTEMS

G. M. GRODSKY, H. SANDO, S. LEVIN, J. GERICH, AND J. KARAM

|   |     |
|---|-----|
| I. Introduction . . . . .   | 155 |
| II. Materials and Methods . . . . .                                 | 156 |
| III. Results and Discussion . . . . .                               | 156 |
| IV. Summary . . . . .   | 166 |
| References . . . . .  | 167 |
| Discussion by Grodsky, Lazarow, Levine, Luft, and Roberts . . . . . | 168 |

## STRUCTURE AND FUNCTION OF THE ENDOCRINE CELL TYPES OF THE ISLETS

PAUL E. LACY

|  |     |
|--|-----|
| I. Introduction . . . . .  | 171 |
| II. Morphology and Hormones of the Islets of Langerhans . . . . .                      | 172 |
| III. Formation of Insulin in the Beta Cell . . . . .                                   | 173 |
| IV. Insulin Release from the Beta Cell . . . . .                                       | 174 |
| V. Microfilaments in Beta Cell Secretion . . . . .                                     | 177 |
| VI. Glucoreceptor of the Beta Cell . . . . .   | 178 |
| VII. Possible Defects in Insulin Release in the Diabetic Subject . . . . .             | 179 |
| VIII. Islet Transplantation . . . . .  | 179 |
| References . . . . .   | 180 |
| Discussion by Baker, Grodsky, Kleeman, Lacy, Levine, Mahler,<br>and Pfeiffer . . . . . | 180 |

## MECHANISMS OF INSULIN ACTION

RACHMIEL LEVINE

|   |     |
|---|-----|
| I. Introduction . . . . .   | 183 |
| II. Factors under Consideration . . . . .   | 184 |
| III. Current Hypotheses Being Tested . . . . .  | 186 |
| References . . . . .  | 187 |
| Discussion by Best, Grodsky, Hastings, Levine, Mahler, Renold, and<br>Roberts . . . . . | 189 |

## DIABETES MELLITUS—A DISEASE OF PANCREATIC AND EXTRAPANCREATIC ORIGIN

E. CERASI AND R. LUFT

|      |  |     |
|------|--|-----|
| I.   | Introduction . . . . .   | 193 |
| II.  | The Mechanisms of the Deranged Insulin Secretion . . . . .                         | 194 |
| III. | Metabolic Consequences of Low Insulin Response (in Nondiabetic Subjects) . . . . . | 202 |
| IV.  | Factors Involved in the Transition from Prediabetes to Diabetes . . . . .          | 205 |
| V.   | Future Aspects of the Prevention and Treatment of Diabetes . . . . .               | 208 |
| VI.  | Conclusions . . . . .  | 209 |
|      | References . . . . .   | 210 |
|      | Discussion by Baker, Grodsky, Lazarow, Levine, Luft, and Mahler . . . . .          | 211 |

## THE PATHOGENESIS OF PANCREATIC ISLET CELL HYPERPLASIA AND INSULIN INSENSITIVITY IN OBESITY

|                   |  |     |
|-------------------|--|-----|
| RICHARD J. MAHLER |  |     |
| I.                | Introduction . . . . .   | 213 |
| II.               | Factors Influencing Islet Function in Obesity . . . . .            | 214 |
| III.              | The Development of Insulin Insensitivity in Obesity . . . . .      | 225 |
| IV.               | Speculations and Conclusions . . . . .                             | 233 |
|                   | References . . . . .   | 237 |
|                   | Discussion by Levine, Luft, Mahler, Pfeiffer, and Renold . . . . . | 240 |

## OBESITY AND DIABETES MELLITUS

E. F. PFEIFFER AND H. LAUBE

|      |   |     |
|------|---|-----|
| I.   | Pathophysiological Features of Obesity . . . . .  | 243 |
| II.  | Clinical Correlation of Obesity and Diabetes Mellitus . . . . .                             | 246 |
| III. | Treatment of Obesity and Prevention of Diabetes by Elimination of Hyperinsulinism . . . . . | 247 |
| IV.  | Summary . . . . .   | 253 |
|      | References . . . . .  | 253 |
|      | Discussion by Bray, Luft, and Pfeiffer . . . . .  | 254 |
|      | Subject Index . . . . .   | 257 |



## KERSTIN HALL\* and ROLF LUFT\*

# Growth Hormone and Somatomedin

|  |    |
|--|----|
| I. Introduction  | 1  |
| II. Sulfation Factor—Somatomedin                               | 3  |
| III. Bioassay of Somatomedin                                   | 4  |
| IV. Occurrence of Somatomedin in Serum                         | 9  |
| A. In Animals  | 9  |
| B. In Man  | 9  |
| V. Purification of Somatomedin                                 | 13 |
| VI. Mechanism of Production of Somatomedin                     | 17 |
| VII. Biological Action of Purified Somatomedin <i>in Vitro</i> | 20 |
| A. On Cartilage  | 20 |
| B. On Adipose Tissue   | 21 |
| C. On Muscle   | 22 |
| D. On Cell Growth  | 23 |
| E. On Cell Membranes   | 23 |
| VIII. Relations between Somatomedins and Other Growth Factors  | 25 |
| A. Insulin   | 26 |
| B. Nonsuppressible Insulinlike Activity (NILA)                 | 26 |
| C. Multiplication-Stimulating Activity (MSA)                   | 27 |
| D. Erythropoietin  | 28 |
| E. Epidermal Growth Factor (EGF)                               | 28 |
| F. Nerve Growth Factor (NGF)                                   | 29 |
| IX. Conclusions  | 29 |
| References   | 31 |

## I. Introduction

One of the classical discoveries in the field of endocrinology is the growth-promoting activity of the anterior part of the pituitary gland.

\* Department of Endocrinology and Metabolism, Karolinska Hospital, Stockholm, Sweden.

It goes back to the demonstration by Evans and Long in 1921 that crude extracts from the anterior lobe of beef pituitary glands produced gigantism in normal plateaued rats by repeated intraperitoneal injections. Later, Smith in 1930 produced dwarfism and sexual infantilism in rats by hypophysectomy, and demonstrated the restoration of growth following the injection of crude pituitary extracts. A period of intense scientific activity followed these observations, concentrating on the different metabolic aspects of growth hormone. Some of the studies were directed toward the different aspects of the growth process itself. Out of the vast number of data in the literature, one may pick the following major findings: that chronic treatment of adult rats with purified growth hormone resulted in an increase in the protein content of the animals (Li and Evans, 1949); that urinary nitrogen excretion diminished and, thus, nitrogen was retained in dogs during treatment with growth hormone; that the primary effect of growth hormone *in vivo* was to stimulate the uptake of amino acids by tissue and their incorporation into protein (Russel, 1955, 1957).

All these effects of growth hormone *in vivo* have one thing in common: they are similar to the *in vivo* and *in vitro* effect of insulin. This similarity between growth hormone and insulin was noted already in 1945 by Young, who then concluded: "There must exist in the body a pituitary-stimulatory mechanism which enhances protein anabolism. The secretion of insulin is capable of fulfilling such a mechanism provided that, under its influence, the blood sugar is not allowed to fall to hypoglycemic levels but is maintained or even elevated." Evidence against the idea that growth hormone acts on protein metabolism by triggering insulin secretion was provided by Manchester and Young (1959), who found that administration of antibodies to insulin did not inhibit the protein stimulation induced by growth hormone.

Since then growth hormone from pituitary glands both from animals and man has been purified, and its chemical structure determined (Li and Evans, 1944; Li *et al.*, 1962; Li and Dixon, 1971). By the use of such preparations it has been well established that growth hormone *in vivo* promotes skeletal growth and protein synthesis. The mechanism involved in these processes have been only partly elucidated (see reviews by Astwood, 1955; Knobil and Greep, 1959; Rabén, 1959; Engel and Kostyo, 1964; Knobil and Hotchkiss, 1964; Sonnenberg, 1968; Tata, 1969; Korner, 1970; Kostyo and Nutting, 1973). The present review will consider the hypothesis that growth hormone promotes protein synthesis by stimulating the appearance in the tissues of a secondary factor, sulfation factor or somatomedin, which transfers the action of the hormone to the tissues.

## II. Sulfation Factor—Somatomedin

The epiphyseal plate of the long bones of the rat declines after hypophysectomy and increases after treatment with growth hormone. This increase in width of the epiphyseal plate of the proximal end of the tibia of hypophysectomized rats accompanying the administration of growth hormone *in vivo* has also been used for quantitative measurements of the hormone (Evans *et al.*, 1943; Greenspan *et al.*, 1949). The incorporation of labeled sulfate into cartilage as chondroitin sulfate provides a useful index of cartilage metabolism. Nearly all the sulfate incorporated by cartilage enters the glucosaminoglycans (Ebert and Prockop, 1967).

The rate of the *in vivo* uptake of sulfate into different cartilaginous tissues of the rat has been shown to decrease after hypophysectomy, and to be restored to normal after parenteral administration of growth hormone (Ellis *et al.*, 1953; Denko and Bergenstal, 1955; Daughaday *et al.*, 1955; Murphy *et al.*, 1956; Collins and Baker, 1960, 1961; Chesley, 1963). Furthermore, the sulfate incorporation *in vivo* into costal cartilage from mice after correction for the size of the exchangeable inorganic sulfate pool of the animal decreased by 30% after hypophysectomy; the following administration of porcine or ovine growth hormone induced a dose-dependant increase (Herbai, 1970, 1971).

The effect of various vitamins and hormones *in vitro* on the uptake of labeled sulfate has been studied extensively. An important observation by Salmon and Daughaday (1957) was that the stimulatory effect on cartilage obtained by growth hormone treatment *in vivo* could not be reproduced by adding growth hormone *in vitro*. Growth hormone had to be added in very high concentrations to the incubation medium before any effect could be detected. In 1956 Salmon, working in the laboratory of Daughaday, made the critical observation that normal serum but not serum from hypophysectomized rats could stimulate the *in vitro* incorporation of labeled sulfate into cartilage of hypophysectomized rats (Salmon and Daughaday, 1956, 1957). Administration of growth hormone to hypophysectomized rats restored the stimulatory activity of their serum. Salmon and Daughaday (1957) concluded that serum contains a factor dependent on growth hormone, and that this factor has a direct effect on cartilage. They termed it *sulfation factor*.

The occurrence in serum of a growth hormone-dependent sulfation factor has been amply confirmed. This factor is not selectively concerned with the introduction of sulfate into glucosaminoglycans but has a more general effect on cartilage. The effects of serum from normal or growth-